Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-10-23

AUTHORS

Naoto Tomita, Yukako Hattori, Shin Fujisawa, Chizuko Hashimoto, Jun Taguchi, Hirotaka Takasaki, Rika Sakai, Ukihide Tateishi, Yoshiaki Ishigatsubo

ABSTRACT

The International Harmonization Project on Lymphoma recommends 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) for the routine assessment of treatment efficacy in patients with FDG-avid lymphomas such as Hodgkin’s and diffuse large B cell lymphomas. The utility of FDG-PET in predicting outcomes in patients with peripheral T cell lymphomas (PTCL) has not been fully elucidated. We retrospectively determined the predictive value of FDG-PET after first-line treatment (post-PET) for outcome in PTCL. Of the 36 patients enrolled, 16 were histologically diagnosed with PTCL not otherwise specified and 20 were diagnosed with angioimmunoblastic T cell lymphoma. All patients received curative-intent anthracycline-containing chemotherapy regimens. Post-PET images were visually evaluated by local nuclear medicine physicians. The median observation period for the surviving patients was 44 months. Positive and negative post-PET results were obtained in 31 % (11/36) and 69 % (25/36) of patients, respectively. The 3-year progression-free survival rates in the positive and negative post-PET result groups were 18 % and 62 %, respectively (P < 0.001). Nine of the 11 patients in the positive post-PET result group experienced progressive disease (PD) (positive predictive value, 82 %), whereas 16 of the 25 patients in the negative post-PET result group did not experience PD (negative predictive value, 64 %). The 3-year overall survival rates in the positive and negative post-PET result groups were 44 % and 84 %, respectively (P = 0.03). Our findings indicate that post-PET is predictive of outcome in patients with PTCL. More... »

PAGES

431-436

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-014-2227-5

DOI

http://dx.doi.org/10.1007/s00277-014-2227-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1025047126

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25338967


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorodeoxyglucose F18", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, T-Cell, Peripheral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron-Emission Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prednisolone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vincristine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tomita", 
        "givenName": "Naoto", 
        "id": "sg:person.01155656464.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155656464.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hattori", 
        "givenName": "Yukako", 
        "id": "sg:person.01107773320.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107773320.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.413045.7", 
          "name": [
            "Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fujisawa", 
        "givenName": "Shin", 
        "id": "sg:person.01145377314.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145377314.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology/Oncology, Yamato Municipal Hospital, Yamato, Japan", 
          "id": "http://www.grid.ac/institutes/grid.460144.3", 
          "name": [
            "Department of Hematology/Oncology, Yamato Municipal Hospital, Yamato, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hashimoto", 
        "givenName": "Chizuko", 
        "id": "sg:person.0663571407.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663571407.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410790.b", 
          "name": [
            "Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Taguchi", 
        "givenName": "Jun", 
        "id": "sg:person.01354366606.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354366606.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takasaki", 
        "givenName": "Hirotaka", 
        "id": "sg:person.0774122402.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774122402.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sakai", 
        "givenName": "Rika", 
        "id": "sg:person.01300452360.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300452360.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tateishi", 
        "givenName": "Ukihide", 
        "id": "sg:person.0742073556.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742073556.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishigatsubo", 
        "givenName": "Yoshiaki", 
        "id": "sg:person.01125133646.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1532/ijh97.03147", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028702381", 
          "https://doi.org/10.1532/ijh97.03147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-008-0494-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016043431", 
          "https://doi.org/10.1007/s00277-008-0494-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11899-011-0098-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023101451", 
          "https://doi.org/10.1007/s11899-011-0098-6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-10-23", 
    "datePublishedReg": "2014-10-23", 
    "description": "The International Harmonization Project on Lymphoma recommends 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) for the routine assessment of treatment efficacy in patients with FDG-avid lymphomas such as Hodgkin\u2019s and diffuse large B cell lymphomas. The utility of FDG-PET in predicting outcomes in patients with peripheral T cell lymphomas (PTCL) has not been fully elucidated. We retrospectively determined the predictive value of FDG-PET after first-line treatment (post-PET) for outcome in PTCL. Of the 36 patients enrolled, 16 were histologically diagnosed with PTCL not otherwise specified and 20 were diagnosed with angioimmunoblastic T cell lymphoma. All patients received curative-intent anthracycline-containing chemotherapy regimens. Post-PET images were visually evaluated by local nuclear medicine physicians. The median observation period for the surviving patients was 44\u00a0months. Positive and negative post-PET results were obtained in 31\u00a0% (11/36) and 69\u00a0% (25/36) of patients, respectively. The 3-year progression-free survival rates in the positive and negative post-PET result groups were 18\u00a0% and 62\u00a0%, respectively (P\u2009<\u20090.001). Nine of the 11 patients in the positive post-PET result group experienced progressive disease (PD) (positive predictive value, 82\u00a0%), whereas 16 of the 25 patients in the negative post-PET result group did not experience PD (negative predictive value, 64\u00a0%). The 3-year overall survival rates in the positive and negative post-PET result groups were 44\u00a0% and 84\u00a0%, respectively (P\u2009=\u20090.03). Our findings indicate that post-PET is predictive of outcome in patients with PTCL.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00277-014-2227-5", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1358129", 
        "issn": [
          "0939-5555", 
          "1432-0584"
        ], 
        "name": "Annals of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "94"
      }
    ], 
    "keywords": [
      "FDG-PET", 
      "progressive disease", 
      "cell lymphoma", 
      "result group", 
      "anthracycline-containing chemotherapy regimens", 
      "progression-free survival rates", 
      "survival rate", 
      "emission tomography", 
      "first-line treatment", 
      "International Harmonization Project", 
      "FDG-avid lymphomas", 
      "median observation period", 
      "overall survival rate", 
      "nuclear medicine physicians", 
      "positron emission tomography", 
      "chemotherapy regimens", 
      "medicine physicians", 
      "patients", 
      "treatment efficacy", 
      "routine assessment", 
      "lymphoma", 
      "predictive value", 
      "observation period", 
      "PTCL", 
      "outcomes", 
      "PET images", 
      "tomography", 
      "group", 
      "regimens", 
      "disease", 
      "physicians", 
      "months", 
      "Harmonization Project", 
      "Hodgkin", 
      "efficacy", 
      "treatment", 
      "rate", 
      "PET", 
      "findings", 
      "assessment", 
      "period", 
      "utility", 
      "results", 
      "values", 
      "images", 
      "project", 
      "curative-intent anthracycline-containing chemotherapy regimens", 
      "local nuclear medicine physicians", 
      "negative post-PET results", 
      "post-PET results", 
      "negative post-PET result groups", 
      "post-PET result groups", 
      "positive post-PET result group"
    ], 
    "name": "Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma", 
    "pagination": "431-436", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1025047126"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-014-2227-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25338967"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-014-2227-5", 
      "https://app.dimensions.ai/details/publication/pub.1025047126"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_639.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00277-014-2227-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-014-2227-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-014-2227-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-014-2227-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-014-2227-5'


 

This table displays all metadata directly associated to this object as RDF triples.

269 TRIPLES      22 PREDICATES      100 URIs      89 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-014-2227-5 schema:about N015631a415e44c2da945930e2614f86c
2 N1431d5624e644e3d92d8077a597767b2
3 N152b2072ed4845c5a0804a2bbc476bbf
4 N1c92fbe32da14a65be664acea0d6ec1d
5 N20368f4ab1054b93b3d443c28bdac54b
6 N2ee03b6683e5470cba115cb271974c62
7 N41e50b0aa2af40359c4981d82e139b53
8 N8accf5f394a9425d9f67b220362e34e1
9 N93ccedb6bc614a06a79aed9f5c33d37f
10 Nc67cbc92f8674ebaaf5fd51b66e2d6b1
11 Nc7a3dc2b93e3418ebc7dcff656b8337c
12 Ne151e8d6df394255a0c1998015049f17
13 Ne4d71bc3db554bd2b15369563eb24ce8
14 Ne5fc81f4c5af451389606bf04c879075
15 Ne77a6e95673040fc8337428e8dabe639
16 Nf2a516ab63d543058cb3eec0ac9ea581
17 Nf8379745955141ae9bcd2d0663030de3
18 Nff9d6ddebdc5411b899209ab55491876
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author N0f4da88349f749fab930f8252c43878c
22 schema:citation sg:pub.10.1007/s00277-008-0494-8
23 sg:pub.10.1007/s11899-011-0098-6
24 sg:pub.10.1532/ijh97.03147
25 schema:datePublished 2014-10-23
26 schema:datePublishedReg 2014-10-23
27 schema:description The International Harmonization Project on Lymphoma recommends 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) for the routine assessment of treatment efficacy in patients with FDG-avid lymphomas such as Hodgkin’s and diffuse large B cell lymphomas. The utility of FDG-PET in predicting outcomes in patients with peripheral T cell lymphomas (PTCL) has not been fully elucidated. We retrospectively determined the predictive value of FDG-PET after first-line treatment (post-PET) for outcome in PTCL. Of the 36 patients enrolled, 16 were histologically diagnosed with PTCL not otherwise specified and 20 were diagnosed with angioimmunoblastic T cell lymphoma. All patients received curative-intent anthracycline-containing chemotherapy regimens. Post-PET images were visually evaluated by local nuclear medicine physicians. The median observation period for the surviving patients was 44 months. Positive and negative post-PET results were obtained in 31 % (11/36) and 69 % (25/36) of patients, respectively. The 3-year progression-free survival rates in the positive and negative post-PET result groups were 18 % and 62 %, respectively (P < 0.001). Nine of the 11 patients in the positive post-PET result group experienced progressive disease (PD) (positive predictive value, 82 %), whereas 16 of the 25 patients in the negative post-PET result group did not experience PD (negative predictive value, 64 %). The 3-year overall survival rates in the positive and negative post-PET result groups were 44 % and 84 %, respectively (P = 0.03). Our findings indicate that post-PET is predictive of outcome in patients with PTCL.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree false
31 schema:isPartOf Na22506844efc4389ae328fb4c0b530fc
32 Naf28bd2fa384415eb1136e7c63a8b54f
33 sg:journal.1358129
34 schema:keywords FDG-PET
35 FDG-avid lymphomas
36 Harmonization Project
37 Hodgkin
38 International Harmonization Project
39 PET
40 PET images
41 PTCL
42 anthracycline-containing chemotherapy regimens
43 assessment
44 cell lymphoma
45 chemotherapy regimens
46 curative-intent anthracycline-containing chemotherapy regimens
47 disease
48 efficacy
49 emission tomography
50 findings
51 first-line treatment
52 group
53 images
54 local nuclear medicine physicians
55 lymphoma
56 median observation period
57 medicine physicians
58 months
59 negative post-PET result groups
60 negative post-PET results
61 nuclear medicine physicians
62 observation period
63 outcomes
64 overall survival rate
65 patients
66 period
67 physicians
68 positive post-PET result group
69 positron emission tomography
70 post-PET result groups
71 post-PET results
72 predictive value
73 progression-free survival rates
74 progressive disease
75 project
76 rate
77 regimens
78 result group
79 results
80 routine assessment
81 survival rate
82 tomography
83 treatment
84 treatment efficacy
85 utility
86 values
87 schema:name Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma
88 schema:pagination 431-436
89 schema:productId N150e4d7ba278430d950ea5decad3163a
90 N5b0a9653b9864856b1b525d01bc1cbf2
91 N74a0aeb8104548b5904e2b0fa0f7d930
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025047126
93 https://doi.org/10.1007/s00277-014-2227-5
94 schema:sdDatePublished 2022-01-01T18:34
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher N28152b50102048fc96a23a3a186db09a
97 schema:url https://doi.org/10.1007/s00277-014-2227-5
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N015631a415e44c2da945930e2614f86c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Cyclophosphamide
103 rdf:type schema:DefinedTerm
104 N045213f0739c4d3ca16ebe280dc4e737 rdf:first sg:person.0663571407.30
105 rdf:rest Naf31298c64cb47bebdfc14361706ecc3
106 N08673a0102414fd19c8b383932f43fea rdf:first sg:person.01107773320.39
107 rdf:rest Nce76cc54732e43e7ae0ac34c746e6e8e
108 N0f4da88349f749fab930f8252c43878c rdf:first sg:person.01155656464.01
109 rdf:rest N08673a0102414fd19c8b383932f43fea
110 N1431d5624e644e3d92d8077a597767b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Middle Aged
112 rdf:type schema:DefinedTerm
113 N150e4d7ba278430d950ea5decad3163a schema:name pubmed_id
114 schema:value 25338967
115 rdf:type schema:PropertyValue
116 N152b2072ed4845c5a0804a2bbc476bbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Aged
118 rdf:type schema:DefinedTerm
119 N1c92fbe32da14a65be664acea0d6ec1d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Positron-Emission Tomography
121 rdf:type schema:DefinedTerm
122 N20368f4ab1054b93b3d443c28bdac54b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Vincristine
124 rdf:type schema:DefinedTerm
125 N28152b50102048fc96a23a3a186db09a schema:name Springer Nature - SN SciGraph project
126 rdf:type schema:Organization
127 N2ee03b6683e5470cba115cb271974c62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Male
129 rdf:type schema:DefinedTerm
130 N41e50b0aa2af40359c4981d82e139b53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Antineoplastic Combined Chemotherapy Protocols
132 rdf:type schema:DefinedTerm
133 N5b0a9653b9864856b1b525d01bc1cbf2 schema:name doi
134 schema:value 10.1007/s00277-014-2227-5
135 rdf:type schema:PropertyValue
136 N74a0aeb8104548b5904e2b0fa0f7d930 schema:name dimensions_id
137 schema:value pub.1025047126
138 rdf:type schema:PropertyValue
139 N7fcdcb958cc042fe9345e9515a9345e0 rdf:first sg:person.0774122402.27
140 rdf:rest Nf0827c55908f4942992d0815e3790134
141 N804c850b8f28480a968230dbc28b27d2 rdf:first sg:person.01125133646.44
142 rdf:rest rdf:nil
143 N8accf5f394a9425d9f67b220362e34e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Female
145 rdf:type schema:DefinedTerm
146 N92100cc5689544149563ec1fc8273e70 rdf:first sg:person.0742073556.08
147 rdf:rest N804c850b8f28480a968230dbc28b27d2
148 N93ccedb6bc614a06a79aed9f5c33d37f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Retrospective Studies
150 rdf:type schema:DefinedTerm
151 Na22506844efc4389ae328fb4c0b530fc schema:volumeNumber 94
152 rdf:type schema:PublicationVolume
153 Naf28bd2fa384415eb1136e7c63a8b54f schema:issueNumber 3
154 rdf:type schema:PublicationIssue
155 Naf31298c64cb47bebdfc14361706ecc3 rdf:first sg:person.01354366606.35
156 rdf:rest N7fcdcb958cc042fe9345e9515a9345e0
157 Nc67cbc92f8674ebaaf5fd51b66e2d6b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Aged, 80 and over
159 rdf:type schema:DefinedTerm
160 Nc7a3dc2b93e3418ebc7dcff656b8337c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Fluorodeoxyglucose F18
162 rdf:type schema:DefinedTerm
163 Nce76cc54732e43e7ae0ac34c746e6e8e rdf:first sg:person.01145377314.06
164 rdf:rest N045213f0739c4d3ca16ebe280dc4e737
165 Ne151e8d6df394255a0c1998015049f17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Treatment Outcome
167 rdf:type schema:DefinedTerm
168 Ne4d71bc3db554bd2b15369563eb24ce8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Humans
170 rdf:type schema:DefinedTerm
171 Ne5fc81f4c5af451389606bf04c879075 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Adult
173 rdf:type schema:DefinedTerm
174 Ne77a6e95673040fc8337428e8dabe639 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Doxorubicin
176 rdf:type schema:DefinedTerm
177 Nf0827c55908f4942992d0815e3790134 rdf:first sg:person.01300452360.13
178 rdf:rest N92100cc5689544149563ec1fc8273e70
179 Nf2a516ab63d543058cb3eec0ac9ea581 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Prednisolone
181 rdf:type schema:DefinedTerm
182 Nf8379745955141ae9bcd2d0663030de3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Lymphoma, T-Cell, Peripheral
184 rdf:type schema:DefinedTerm
185 Nff9d6ddebdc5411b899209ab55491876 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Prognosis
187 rdf:type schema:DefinedTerm
188 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
189 schema:name Medical and Health Sciences
190 rdf:type schema:DefinedTerm
191 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
192 schema:name Oncology and Carcinogenesis
193 rdf:type schema:DefinedTerm
194 sg:journal.1358129 schema:issn 0939-5555
195 1432-0584
196 schema:name Annals of Hematology
197 schema:publisher Springer Nature
198 rdf:type schema:Periodical
199 sg:person.01107773320.39 schema:affiliation grid-institutes:grid.414944.8
200 schema:familyName Hattori
201 schema:givenName Yukako
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107773320.39
203 rdf:type schema:Person
204 sg:person.01125133646.44 schema:affiliation grid-institutes:grid.268441.d
205 schema:familyName Ishigatsubo
206 schema:givenName Yoshiaki
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44
208 rdf:type schema:Person
209 sg:person.01145377314.06 schema:affiliation grid-institutes:grid.413045.7
210 schema:familyName Fujisawa
211 schema:givenName Shin
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145377314.06
213 rdf:type schema:Person
214 sg:person.01155656464.01 schema:affiliation grid-institutes:grid.268441.d
215 schema:familyName Tomita
216 schema:givenName Naoto
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155656464.01
218 rdf:type schema:Person
219 sg:person.01300452360.13 schema:affiliation grid-institutes:grid.414944.8
220 schema:familyName Sakai
221 schema:givenName Rika
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300452360.13
223 rdf:type schema:Person
224 sg:person.01354366606.35 schema:affiliation grid-institutes:grid.410790.b
225 schema:familyName Taguchi
226 schema:givenName Jun
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354366606.35
228 rdf:type schema:Person
229 sg:person.0663571407.30 schema:affiliation grid-institutes:grid.460144.3
230 schema:familyName Hashimoto
231 schema:givenName Chizuko
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663571407.30
233 rdf:type schema:Person
234 sg:person.0742073556.08 schema:affiliation grid-institutes:grid.268441.d
235 schema:familyName Tateishi
236 schema:givenName Ukihide
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742073556.08
238 rdf:type schema:Person
239 sg:person.0774122402.27 schema:affiliation grid-institutes:grid.414944.8
240 schema:familyName Takasaki
241 schema:givenName Hirotaka
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774122402.27
243 rdf:type schema:Person
244 sg:pub.10.1007/s00277-008-0494-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016043431
245 https://doi.org/10.1007/s00277-008-0494-8
246 rdf:type schema:CreativeWork
247 sg:pub.10.1007/s11899-011-0098-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023101451
248 https://doi.org/10.1007/s11899-011-0098-6
249 rdf:type schema:CreativeWork
250 sg:pub.10.1532/ijh97.03147 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028702381
251 https://doi.org/10.1532/ijh97.03147
252 rdf:type schema:CreativeWork
253 grid-institutes:grid.268441.d schema:alternateName Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
254 Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
255 schema:name Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
256 Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
257 rdf:type schema:Organization
258 grid-institutes:grid.410790.b schema:alternateName Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan
259 schema:name Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan
260 rdf:type schema:Organization
261 grid-institutes:grid.413045.7 schema:alternateName Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
262 schema:name Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
263 rdf:type schema:Organization
264 grid-institutes:grid.414944.8 schema:alternateName Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
265 schema:name Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
266 rdf:type schema:Organization
267 grid-institutes:grid.460144.3 schema:alternateName Department of Hematology/Oncology, Yamato Municipal Hospital, Yamato, Japan
268 schema:name Department of Hematology/Oncology, Yamato Municipal Hospital, Yamato, Japan
269 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...